Prostate Cancer Blog for Wives and Partners

The Prostate Cancer Blog for Wives and Partners lets you know when new information has been added to our site. Anytime a new page is created — or we feel there is something worth noting — it will be posted here.

Archive of older posts

Men: Move More With Prostate Cancer

Another study is touting the benefits of moderate to high-level physical activity to help improve a man's chance of surviving prostate cancer. A reduced risk of prostate cancer specific mortality (death) has already been associated with vigorous physical activity, both before and after a man is diagnosed, according to research by Wang et al, which was presented at the American Association for Cancer Research Annual Meeting this week. Now, researchers say that “sitting time” (watching television, reading, sitting or driving in a car, etc.) is not associated with a reduced risk of prostate cancer specific mortality. The researchers looked at data from more than 10,000 men (ages 50 to 93) who did not have metastatic prostate cancer. Men who exercised the most had a 35 percent lower risk of dying from prostate cancer than men who exercised the least. April 19, 2016.

Continue reading "Men: Move More With Prostate Cancer"

How Safe Is Active Surveillance?

One of the challenges of active surveillance (sometimes called watchful waiting) is that there is no way to predict if — or when — cancer may spread. Now researchers are telling us that more than three percent of men who are on active surveillance had prostate cancer metastasis, according to a new study (Yamamoto et al) published in the The Journal of Urology. In this single center, prospective cohort study, 30 of 980 men experienced prostate cancer metastasis. The median age of men was 70 years, median PSA was 6.2 ng/ml, and median time to metastasis was 8.9 years. Median follow up was 6.3 years. The study authors conclude that active surveillance may be safe in men at low risk and certain patients at intermediate risk (Gleason score 6 and PSA > 10 ng/ml). April 16, 2016

Study: Higher Dose Of Radiation In Shorter Timeframe May Be Just As Effective For Men With Early Prostate Cancer

Men with low-risk prostate cancer who receive a slightly higher dose of radiation for 5.6 weeks may be able to control their prostate cancer as well as men who receive standard radiation for 8 weeks, according to a new study (Lee at al) published in the Journal of Clinical Oncology. At five years, overall survival and disease-free survival were the same between both groups. April 13, 2016.

Continue reading "Study: Higher Dose Of Radiation In Shorter Timeframe May Be Just As Effective For Men With Early Prostate Cancer"

Study: Timing Of Hormone Treatment And Immunotherapy Is Important

Using animal (mouse) models, researchers have discovered that many types of androgen deprivation therapy may suppress a man’s adaptive immune responses — which could prevent immunotherapies from being effective — if both treatments are not timed properly. These findings come from a study (Yang et al) that was published in Science Translational Medicine. More studies are needed, but this is definitely something to discuss with your doctor if you will be receiving both types of therapies. April 8, 2016.

Study: Higher Survival Rate For Men Treated At Busy Radiation Centers

Men who received radiation treatment for prostate cancer from centers that frequently perform radiation therapy had a better overall survival rate, according to a new study (Chen et al) published in the International Journal of Radiation Oncology, Biology, and Physics. When researchers analyzed data from more than 19,500 men with prostate cancer who were treated with radiation at 1,099 facilities, they found a small difference in the 7-year overall survival of men who were treated at a facility in the top 20 percent for radiation volume (76% vs 74%) compared to men treated at centers in the bottom 80% percent for radiation volume. A center that treated over 43 men per year was considered to be in the top 20 percent for radiation volume. March 28, 2016.

Study: Location of Prostate Cancer Metastasis Affects Survival Time

Men who have prostate cancer that spreads only to the lymph nodes may survive longer than men who have disease that has spread to other areas, according to a new study (Halabi et al) published in the Journal of Clinical Oncology. When researchers analyzed data from 8,820 men with prostate cancer they found that men with liver metastases had the lowest median overall survival (MOS) of 13.5 months. Men with lung metastases had MOS of 19.4 months. Men with nonvisceral bone metastases had MOS of 21.3 months and men with lymph node only metastases had MOS of 31.6 months. March 14, 2016.

Link Between Low Vitamin D and Aggressive Prostate Cancer?

Men with low vitamin D levels were more likely to have fast growing prostate cancer tumors than men with normal levels, according to a new study (Nyame et al), which was published in the Journal of Clinical Oncology. In this study of 190 men who had their prostate glands removed via surgery, close to 46 percent of men had more aggressive prostate cancer. A significant number of those men also had low vitamin D (called serum 25-OH D) levels before they had surgery. If these findings can be confirmed by a much larger study, serum 25-OH D levels may be a useful biomarker to predict aggressiveness of the disease. March 3, 2016.

Seeing the Light During Prostate Cancer Surgery

Researchers have found a way to tell the difference between malignant and benign prostate tissue with a reported 85 percent sensitivity, 86 percent specificity, and 86 percent accuracy, according to a small study that was recently published in the Journal of Urology. Researchers at UT Southwestern Medical Center used a tool called light reflectance spectroscopy (LRS) to analyze 17 prostate gland specimens after they were removed during surgery. LRS measures light intensity that is reflected or backscattered from tissues. While further studies are needed, LRS may one day help surgeons determine in real time how much tissue surrounding the prostate gland needs to be removed (called surgical margins). February 29, 2016.

Male Baldness: Risk Factor for Prostate Cancer Death?

Male pattern baldness has long been associated with an increased risk of prostate cancer in observational studies (studies that draw influences from a sample to a population but the independent variable is not under the control of the researcher). Now results of a prospective study that followed men over time (called the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study or NHEFS) suggest that bald men have a 1.5 times greater risk of death due to prostate cancer. Researchers looked at data from 4,316 men in the study (called a cohort) who had no previous cancer diagnosis at baseline and were 25 to 74 years old. Of that number, 107 men died from prostate cancer. Before baldness can be considered a conclusive risk factor for prostate cancer, the study results should be replicated. February 20, 2016.

Continue reading "Male Baldness: Risk Factor for Prostate Cancer Death?"

New Prognostic Biomarker May Help Determine Treatment Timeline

Researchers working at the University of Copenhagen have discovered a new prognostic biomarker that is very specific to prostate cancer cells (a neuropeptide called pro-NPY), which may help predict a man’s risk of dying from the disease. It may also help doctors determine if a man should have surgery (radical prostatectomy) when he is first diagnosed with prostate cancer, or whether surgery can safely be delayed. February 16, 2016.

Join the Prostate Cancer Registry

Prostate cancer survivors are being invited to share their experiences in a web-based Prostate Cancer Registry that was developed by the Center for Cancer Research and Therapeutic Development at Clark Atlanta University in partnership with the Georgia Prostate Cancer Coalition. The registry is designed to gather information about men’s experiences and needs, which will be used to fuel research. It will also monitor trends and changes in the epidemiological, emotional, and health status of prostate cancer survivors. February 9, 2016.

Continue reading "Join the Prostate Cancer Registry"

Aspirin For Prostate Cancer (Again)

Aspirin is back in the news again. This time, researchers believe it may help cut the risk of death in men who have prostate cancer. Before you reach for the aspirin bottle, know that this was a study where researchers looked at data from 22,017 men (3,193 developed prostate cancer) who participated in Harvard University’s Physician’s Health Study over a period of 27 years. Of those men, 402 developed lethal cancer. Men who took more than 3 aspirin tablets a week were 24% less likely to die from the disease. But this was not a randomized controlled study so there may have been other factors that could influence outcomes. Due to bleeding risk, always check with your doctor before starting an aspirin regimen. January 24, 2016.

Obesity and Prostate Cancer

The association between being overweight and aggressive prostate cancer just got clearer. Researchers (Laurent et al) now know that a fatty deposit that surrounds the prostate (called periprostatic adipose tissue) may be invaded by tumor cells, which can lead to prostate cancer spreading to nearby organs. This happens more frequently in obese men due to the fact that they have more fatty deposit cells (called adipocyte cells). When these cells secrete chemokines (signaling proteins), they attract prostate cancer tumor cells. January 20, 2016.

Exercise As Treatment For Prostate Cancer?

Researchers in the United Kingdom are launching a small study (50 men) to see if exercise may be effective as a treatment for prostate cancer that has not spread (called localized prostate cancer). Twenty-five men will exercise two-and-a-half hours every week for a year with a trainer. The other 25 men will be given information about the benefits of exercise but will not be supervised. While this is not what we would consider to be a large or robust clinical trial, we’ll be eager to see the results. January 16, 2016.

New Grading System for Prostate Cancer

Choosing treatment options may be easier with a new five-tiered grading system for prostate cancer, according to researchers at Johns Hopkins, who developed it. The new system is based on data from more than 20,000 men. While the current Gleason System has 25 possible scores, with the new system, 1 is the least aggressive cancer and 5 is the most aggressive. It remains to be seen how quickly the new system will be endorsed by leading U.S. medical organizations. So far, the World Health Organization and the International Society of Urological Pathology are on board with it. January 11, 2016.

Always consult a medical professional.

Page copy protected against web site content infringement by Copyscape
Search site
Search site